Atara Biotherapeutics Inc  

(Public, NASDAQ:ATRA)   Watch this stock  
Find more results for John T. Isaacs, Ph.D.�
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 9.66 - 64.35
Open     -
Vol / Avg. 0.00/207,161.00
Mkt cap 919.26M
P/E     -
Div/yield     -
EPS -3.05
Shares 24.36M
Beta     -
Inst. own 74%
May 7, 2015
Q1 2015 Atara Biotherapeutics Inc Earnings Release
Apr 14, 2015
Atara Biotherapeutics Inc at Needham Healthcare Conference
Feb 26, 2015
Q4 2014 Atara Biotherapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -26.63% -35.46%
Return on average equity -27.29% -60.77%
Employees 18 -
CDP Score - -


3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States - Map
+1-415-2872410 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The Company’s research is based on the ability of activin, myostatin and other growth factors to change the course of disease progression. Atara Biotherapeutics’ is developing several independent programs: PINTA 745, STM 434 and ATA 842. The Company operates and manages its business as a reporting and operating segment, which is the business of developing and commercializing therapeutics. PINTA 745 is a peptibody, a protein construct made of a synthetic peptide that is fused to an antibody that binds to and blocks growth factors in the transforming growth factor beta pathway. Peptibodies are an established class of biologic therapies. STM 434 is a soluble receptor fused to part of an antibody that blocks the growth factor activin-A.

Officers and directors

Isaac E. Ciechanover M.D. President, Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
John F. McGrath Jr. Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Gad Soffer Chief Operating Officer
Age: 38
Bio & Compensation  - Reuters
Mitchall G. Clark Chief Regulatory and Quality Assurance Officer
Age: 54
Bio & Compensation  - Reuters
Christopher M. Haqq M.D., Ph.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Carol Giltner Gallagher Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Eric L. Dobmeier Director
Age: 46
Bio & Compensation  - Reuters
Eckard Weber M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Joel S. Marcus J.D., CPA Independent Director
Age: 67
Bio & Compensation  - Reuters